Status:
UNKNOWN
Effect of Remimazolam on Postoperative Delirium
Lead Sponsor:
Zhihong LU
Conditions:
General Anesthetic Drug Adverse Reaction
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
Remimazolam is a novel benzodiazepine with ultra-short onset and offset of its effect. It can be used for general anesthesia. However, classical benzodiazepine such as midazolam was reported to increa...
Eligibility Criteria
Inclusion
- Age ≥65 years
- patients scheduled for elective surgery under general anesthesia
Exclusion
- American Society of Anesthesiologists status ≥Ⅳ
- history of neurologic or psychiatric diseases
- difficulty in communication
- abuse of drug or alcohol
- suspected allergy to propofol or benzodiazepines
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2024
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT06180876
Start Date
May 25 2022
End Date
January 30 2024
Last Update
December 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing hospital, Fourth military medical university
Xi'an, Shaanxi, China, 710032